To determine the prevalence and average impact of symptoms and symptomatic themes experienced by adults with myasthenia gravis (MG) and to use this information to develop a regulatory-grade outcome measure for this population.
No takes yet. Share an insight, caveat, or question.
Engebrecht et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: